TBC1D32

Across TCGA pan-cancer cohorts, TBC1D32 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TBC1D32 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TBC1D32 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TBC1D32 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UCEC, SKCM, and SARC are the cancer types where TBC1D32 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.941	0.433	.011	24	view →
SKCM	DFS	Median	II,III,IV	0.849	0.550	.003	16	view →
SARC	DFS	Median	All	0.182	0.612	.026	11	view →
LIHC	DFS	Median	II,III,IV	0.104	0.429	.028	3	view →
BLCA	OS	Median	II,III,IV	1.000	0.411	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TBC1D32–UCEC (DFS)

Open the UCEC breakdown →